![BriaCell Therapeutics Corp](/common/images/company/T_BCT.png)
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ monotherapyNo toxicity related to the treatment; Patient remains on...
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaPro Therapeutics Corp. (“BriaPro” or the “Company”), a pre-clinical stage immunotherapy company developing binding agents and...
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell reports influx of cancer fighting CD8+ “killer” T cell into metastatic breast cancer tumors and lymph organs turning “Cold” tumors and lymph nodes “Hot” on ImmunoPET imaging in cancer...
PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.54 | -19.2019950125 | 8.02 | 10.7 | 5.68 | 40757 | 7.31726891 | CS |
4 | -3.27 | -33.5384615385 | 9.75 | 10.7 | 5.68 | 43084 | 8.43057687 | CS |
12 | -7.17 | -52.5274725275 | 13.65 | 27.45 | 5.68 | 71507 | 13.97780293 | CS |
26 | -6.27 | -49.1764705882 | 12.75 | 37.95 | 5.68 | 59914 | 14.98934346 | CS |
52 | -71.82 | -91.724137931 | 78.3 | 86.85 | 5.68 | 35442 | 18.27377027 | CS |
156 | -117.57 | -94.7762998791 | 124.05 | 225.75 | 5.68 | 16643 | 51.47893611 | CS |
260 | -156.12 | -96.0147601476 | 162.6 | 225.75 | 5.68 | 16321 | 52.55654715 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約